Lyra Therapeutics

📍 Watertown, United States🗓 Founded 2018👥 76 employees💰 Last funded Apr 2022
Biotechnology Research🌐 lyratx.com
Website LinkedIn
Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. Building on expertise in materials science, drug development and formulation, Lyra has developed proprietary technology that is designed to deliver medicines directly precisely and consistently to the affected tissue for sustained periods with a single administration. Our product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, in-office procedure and intended to deliver up to six months of continuous mometasone furoate drug therapy to the sinonasal passages for the treatment of CRS.
5
Total investors
4
Early stage
1
Mid stage
0
Late stage
2018
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Investor activity2015–2022 · investors recorded per year
2015120181201912020120221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Lyra Therapeutics?
Lyra Therapeutics has 5 investors on record on gritt.io, including 4 early-stage backers, 1 mid-stage.
When did Lyra Therapeutics last raise funding?
The most recent investment in Lyra Therapeutics recorded on gritt.io was in April 2022.
When was Lyra Therapeutics founded?
Lyra Therapeutics was founded in 2018.
What industry is Lyra Therapeutics in?
Lyra Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Lyra Therapeutics based?
Lyra Therapeutics is headquartered in Watertown, United States.